Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
2
Neutral
4
Bullish
8
Bearish
34
Neutral
4
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Discovery themes featuring this stock
Anupam Rasayan India Ltd. is an established Indian specialty chemical and custom synthesis manufacturer that undertakes complex multi-step syntheses across life-science related specialty chemicals and performance materials, operating six manufacturing sites with ~30,000+ MT capacity and a DSIR-recognized R&D centre of 90+ scientists to serve global MNC customers.
Financially, the company reported consolidated 9MFY26 revenue of ₹17,297 million (up 84% YoY), EBITDA of ₹4,024 million (up 53% YoY) and PAT of ₹1,662 million (up 71% YoY), driven by ramp-up of recently commercialized molecules and stronger execution of a large LOI/contract pipeline that materially increased revenue visibility.
Strategically significant moves include a definitive agreement to acquire Jayhawk Fine Chemicals in the U.S. (enterprise value ~$134M; total consideration ~$150M) to secure onshore manufacturing, high-purity tech and customer access, and earlier acquisition of a ~26% stake in Tanfac to backward integrate fluorination feedstocks and reduce supply-chain risk.
The company emphasises a differentiated fluorination platform and backward integration, with a disclosed $220–$260 million revenue potential from targeted fluorination series and a separately signed battery-chemicals LOI (LiPF6) valued at ₹3,000 crore, indicating a focused push into high-value, less cyclical end-markets like electronics and battery materials.
Operationally, Anupam Rasayan India Ltd. has converted LOIs into commercial revenue, improved asset utilisation and is targeting meaningful working-capital intensity improvements (management target: consolidated working capital days below ~180 by FY27), highlighting execution discipline alongside growth initiatives.
Chemicals & Petrochemicals
Specialty Chemicals
14,222 Cr
Low Risk
83.6
44.1
1.1
4.3
1,415.40
1,047.40
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
477.35 | 17,315 Cr | 42.02 | 2.91 | 0.21 | 7.04 | 6.41 | 3.15 | ||
3670.00 | 15,887 Cr | 38.45 | 4.01 | 0.68 | 10.62 | 14.23 | 4.98 | ||
4787.00 | 14,814 Cr | 35.97 | 5.56 | 0.23 | 15.65 | 20.00 | 13.91 | ||
1232.00 | 14,222 Cr | 83.61 | 4.31 | 0.12 | 5.10 | 7.68 | 2.77 | ||
3580.00 | 14,045 Cr | 42.92 | 9.94 | 0.28 | 23.19 | 21.43 | 9.99 | ||
1306.90 | 13,487 Cr | 30.40 | 4.27 | 0.65 | 14.03 | 18.72 | 12.36 | ||
725.00 | 11,556 Cr | 36.35 | 3.70 | 0.34 | 8.89 | 10.37 | 5.63 | ||
| Median: 7 Co. | — | 1306.90 | 14,222 Cr | 38.45 | 4.27 | 0.28 | 10.62 | 14.23 | 5.63 |
Anupam Rasayan India Ltd (ANURAS) is currently trading at 1,232.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anupam Rasayan India Ltd. is an established Indian specialty chemical and custom synthesis manufacturer that undertakes complex multi-step syntheses across life-science related specialty chemicals and performance materials, operating six manufacturing sites with ~30,000+ MT capacity and a DSIR-recognized R&D centre of 90+ scientists to serve global MNC customers. Financially, the company reported consolidated 9MFY26 revenue of ₹17,297 million (up 84% YoY), EBITDA of ₹4,024 million (up 53% YoY) and PAT of ₹1,662 million (up 71% YoY), driven by ramp-up of recently commercialized molecules and stronger execution of a large LOI/contract pipeline that materially increased revenue visibility. Strategically significant moves include a definitive agreement to acquire Jayhawk Fine Chemicals in the U.S. (enterprise value ~$134M; total consideration ~$150M) to secure onshore manufacturing, high-purity tech and customer access, and earlier acquisition of a ~26% stake in Tanfac to backward integrate fluorination feedstocks and reduce supply-chain risk. The company emphasises a differentiated fluorination platform and backward integration, with a disclosed $220–$260 million revenue potential from targeted fluorination series and a separately signed battery-chemicals LOI (LiPF6) valued at ₹3,000 crore, indicating a focused push into high-value, less cyclical end-markets like electronics and battery materials. Operationally, Anupam Rasayan India Ltd. has converted LOIs into commercial revenue, improved asset utilisation and is targeting meaningful working-capital intensity improvements (management target: consolidated working capital days below ~180 by FY27), highlighting execution discipline alongside growth initiatives.
Over the past 52 weeks, Anupam Rasayan India Ltd has traded between a low of ₹1,047.40 and a high of ₹1,415.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anupam Rasayan India Ltd has a market capitalization of approximately 14,221.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anupam Rasayan India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 83.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 14,221.93 Cr, Anupam Rasayan India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anupam Rasayan India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anupam Rasayan India Ltd is 83.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a mandatory cash open offer filed with SEBI to buy up to 2,77,26,848 Bliss GVS Pharma shares, representing 26% of the expanded voting share capital.
Anupam Rasayan is acquiring Jayhawk Fine Chemicals for $150 million, giving it an onshore manufacturing base in the United States.
It announced commercialisation of ETFA (Ethyl trifluoroacetate) using its proprietary continuous flow chemistry platform, shifting the process from batch to continuous flow.
The company said it has commercialised ETFA (Ethyl Trifluoroacetate) production using its proprietary process-by-design continuous flow chemistry platform.
Open Offer
Anupam Rasayan India Ltd submitted the Letter of Offer for a cash open offer to acquire 27,726,848 shares (26% of expanded voting capital) of Bliss GVS Pharma at ₹299 per share, alongside PAC Mates Visa Consultancy.
Regulatory/Compliance Filing
Anupam Rasayan India Ltd submitted the Letter of Offer (dated July 21, 2026) for an open offer to acquire 27,726,848 equity shares (26%) of Bliss GVS Pharma at ₹299 per share with PAC Mates Visa Consultancy.
